On behalf of all of us at Editas Medicine, we wish everyone a safe, healthy, and happy Independence Day!
Editas Medicine
Biotechnology Research
Cambridge, Massachusetts 44,283 followers
What If You Could Repair Broken Genes?
About us
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
- Website
-
http://www.editasmedicine.com
External link for Editas Medicine
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2013
- Specialties
- Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
Locations
-
Primary
11 Hurley St
Cambridge, Massachusetts 02141, US
-
4909 Nautilus Ct N
Suite 208/211
Boulder, Colorado 80301, US
Employees at Editas Medicine
Updates
-
We had a great month filled with Pride celebrations at Editas Medicine! We are proud to show our support as allies and members of the LGBTQ community. #InsideEditas
-
Next week, our offices will be closed for our annual summer shutdown. We hope our Editors have a safe and happy week off and enjoy some well-deserved rest and relaxation! #InsideEditas
-
Congratulations to our Northeastern University co-ops on completing their co-op term at Editas Medicine! We have enjoyed having you at Editas and are so proud of all of your accomplishments. We wish you all the best as you go on to do great things! #InsideEditas #biotechnology #geneediting
-
Yesterday, our team of Editors united in support of our blood drive, hosted in recognition of #WorldSickleCellDay. Together, we collected more than 40 pints of blood. Thank you to all who donated, organized the drive, and extended their support. #ShinetheLightonSickleCell
-
This #Juneteenth, we unite for #WorldSickleCellDay. Sickle cell disease, a blood disorder, disproportionately affects people of African descent. People with the condition often need blood transfusions during a sickle cell crisis. Editas is closed today in observance of Juneteenth and tomorrow we are hosting a blood drive in recognition of the sickle cell community. #ShinetheLightonSickleCell
-
With #WorldSickleCellDay coming up on June 19, the Editas Medicine team is honored to listen and learn from Jacqueline Haley, Executive Director at Massachusetts Sickle Cell Association, as she shares why this day is so important and offers inspiration to get involved. This week, our team members will take part in a blood drive to raise awareness and show our support for people with sickle cell disease who rely on blood transfusions as a mainstay of treatment. #ShinetheLightonSickleCell
-
Today, Editas Medicine President & CEO Gilmore O’Neill sat down with industry leaders to discuss targeted licensing and acquisitions at the Longwood Healthcare Leaders Spring MIT. #longwoodhealthcareleaders #biotechnology
Wonderful insights on M&A and licensing shared by David Meek, Editas Medicine CEO Gilmore ONeill, Servier Pharmaceuticals CBO Deniz Razon Arbor Biotechnologies CEO Devyn Smith & Fish & Richardson P.C. Caleb Bates, JD, PhD
-
Yesterday, we reported new safety and efficacy data from the RUBY trial of reni-cel in 18 patients with sickle cell disease at #EHA2024. Learn more: bit.ly/3VikpC6 #EHA2024 #geneediting #sicklecelldisease
-
Good morning from #EHA2024! Today, we are presenting clinical data from the RUBY trial of reni-cel for the treatment of severe sickle cell disease. Learn more: bit.ly/3VikpC6 #sicklecelldisease #geneediting #biotechnology